DR REDDY'S Q2: INDIA REVENUE UP 17% YOY; EMERGING MARKETS GROW 24%, NORTH AMERICA DECLINES 23%

• Global Generics: Revenue down 0.7% YoY to ₹7,790 Cr, up 8% QoQ • North America: Revenue down 23% YoY to ₹2,490 Cr, up 13% QoQ, impacted by lower Lenalidomide sales • India Business: Revenue up 17% YoY to ₹1,850 Cr, up 8% QoQ, driven by new launches, pricing and volume growth • Emerging Markets: Revenue up 24% YoY to ₹2,060 Cr, up 12% QoQ, supported by Russia and favourable currency movements • Russia Business: Revenue up 15% YoY to ₹1,010 Cr, up 12% QoQ • Rest of World: Revenue up 9% YoY to ₹790 Cr, up 11% QoQ • Europe Business: Revenue up 1% YoY to ₹1,390 Cr, down 3% QoQ, impacted by generic pricing pressure • European NRT Business: Revenue down 6% YoY to ₹660 Cr, flat QoQ • Product Launches: Launched 27 products across emerging markets and 6 products each in North America and Europe during Q2 • US Pipeline: 80 ANDA filings pending USFDA approval, including 27 with potential first-to-file status • India Market Position: Ranked 8th in the Indian pharmaceutical market on a moving quarterly basis, outperforming industry growth

DR. REDDY S LABORATORIES

← Back to feed